Pacer Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $71.8M | Buy |
59,898
+20,246
| +51% | +$20.7M | 0.18% | 134 |
|
|
2026
Q1 | $36.5M | Sell |
39,652
-22,352
| -36% | -$22.7M | 0.1% | 213 |
|
|
2025
Q4 | $66.6M | Sell |
62,004
-1,853
| -3% | -$1.77M | 0.17% | 133 |
|
|
2025
Q3 | $48.7M | Buy |
63,857
+293
| +0.5% | +$218K | 0.12% | 181 |
|
|
2025
Q2 | $49.6M | Buy |
63,564
+23,317
| +58% | +$18.1M | 0.12% | 178 |
|
|
2025
Q1 | $33.2M | Sell |
40,247
-22,486
| -36% | -$18.7M | 0.08% | 218 |
|
|
2024
Q4 | $48.4M | Buy |
62,733
+3,934
| +7% | +$3.26M | 0.1% | 207 |
|
|
2024
Q3 | $52.1M | Sell |
58,799
-9,218
| -14% | -$8.29M | 0.11% | 205 |
|
|
2024
Q2 | $61.6M | Buy |
68,017
+3,713
| +6% | +$2.97M | 0.14% | 179 |
|
|
2024
Q1 | $50M | Sell |
64,304
-13,802
| -18% | -$9.82M | 0.12% | 193 |
|
|
2023
Q4 | $45.5M | Buy |
78,106
+12,904
| +20% | +$7.53M | 0.13% | 180 |
|
|
2023
Q3 | $35M | Buy |
65,202
+3,329
| +5% | +$1.72M | 0.13% | 169 |
|
|
2023
Q2 | $29M | Buy |
61,873
+2,914
| +5% | +$1.22M | 0.12% | 174 |
|
|
2023
Q1 | $20.2M | Buy |
58,959
+56,177
| +2,019% | +$18.9M | 0.09% | 232 |
|
|
2022
Q4 | $1.02M | Sell |
2,782
-711
| -20% | -$252K | 0.01% | 824 |
|
|
2022
Q3 | $1.13M | Buy |
3,493
+264
| +8% | +$83.6K | 0.01% | 516 |
|
|
2022
Q2 | $1.05M | Sell |
3,229
-37,604
| -92% | -$11.3M | 0.01% | 537 |
|
|
2022
Q1 | $11.7M | Sell |
40,833
-10,456
| -20% | -$2.69M | 0.1% | 209 |
|
|
2021
Q4 | $14.2M | Buy |
51,289
+2,430
| +5% | +$616K | 0.15% | 124 |
|
|
2021
Q3 | $11.3M | Buy |
48,859
+2,054
| +4% | +$507K | 0.14% | 180 |
|
|
2021
Q2 | $10.7M | Buy |
46,805
+3,184
| +7% | +$640K | 0.15% | 113 |
|
|
2021
Q1 | $8.15M | Sell |
43,621
-5,689
| -12% | -$1.11M | 0.14% | 121 |
|
|
2020
Q4 | $8.33M | Sell |
49,310
-10,984
| -18% | -$1.64M | 0.16% | 97 |
|
|
2020
Q3 | $8.93M | Sell |
60,294
-14,168
| -19% | -$2.19M | 0.19% | 90 |
|
|
2020
Q2 | $12.2M | Buy |
+74,462
| New | +$11.4M | 0.25% | 72 |
|
|
2020
Q1 | – | Sell |
-96,685
| Closed | -$12.7M | – | 914 |
|
|
2019
Q4 | $12.7M | Buy |
96,685
+2,913
| +3% | +$338K | 0.57% | 21 |
|
|
2019
Q3 | $10.5M | Buy |
93,772
+4,572
| +5% | +$509K | 0.24% | 75 |
|
|
2019
Q2 | $9.88M | Buy |
89,200
+6,957
| +8% | +$819K | 0.24% | 73 |
|
|
2019
Q1 | $10.7M | Buy |
+82,243
| New | +$10M | 0.3% | 61 |
|
|
2018
Q4 | – | Sell |
-51,226
| Closed | -$5.5M | – | 824 |
|
|
2018
Q3 | $5.5M | Buy |
51,226
+6,450
| +14% | +$645K | 0.21% | 82 |
|
|
2018
Q2 | $3.82M | Buy |
44,776
+7,564
| +20% | +$621K | 0.17% | 96 |
|
|
2018
Q1 | $2.88M | Buy |
37,212
+4,189
| +13% | +$337K | 0.16% | 114 |
|
|
2017
Q4 | $2.79M | Buy |
33,023
+9,407
| +40% | +$800K | 0.2% | 82 |
|
|
2017
Q3 | $2.02M | Buy |
23,616
+2,215
| +10% | +$182K | 0.18% | 82 |
|
|
2017
Q2 | $1.76M | Buy |
21,401
+1,650
| +8% | +$135K | 0.17% | 87 |
|
|
2017
Q1 | $1.66M | Buy |
19,751
+1,347
| +7% | +$108K | 0.2% | 64 |
|
|
2016
Q4 | $1.35M | Sell |
18,404
-668
| -4% | -$49.7K | 0.19% | 70 |
|
|
2016
Q3 | $1.53M | Buy |
19,072
+133
| +0.7% | +$10.6K | 0.23% | 59 |
|
|
2016
Q2 | $1.49M | Buy |
18,939
+1,731
| +10% | +$130K | 0.24% | 62 |
|
|
2016
Q1 | $1.24M | Buy |
17,208
+969
| +6% | +$73.3K | 0.28% | 70 |
|
|
2015
Q4 | $1.37M | Buy |
+16,239
| New | +$1.35M | 0.32% | 64 |
|
|
2013
Q4 | $433K | Buy |
+6,283
| New | +$315K | 0.1% | 248 |
|
Other funds holding LLY
Pacer Advisors's LLY Position: Q2 2026 in Review
Pacer Advisors increased its Eli Lilly (LLY) stake by 51% in Q2 2026, buying an estimated $20.7M and bringing the position to 59,898 shares worth $71.8M. The position accounts for 0.18% of the portfolio, ranked #134.
Pacer Advisors first reported a position in LLY in Q4 2013 and has held it in 42 quarters since. 4,598 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Pacer Advisors held 59,898 shares of Eli Lilly worth $71.8M as of Q2 2026.
- Pacer Advisors bought 20,246 Eli Lilly shares in Q2 2026, an estimated $20.7M.
- Eli Lilly made up 0.18% of Pacer Advisors's portfolio in Q2 2026, its #134 holding.
- Pacer Advisors first reported a position in Eli Lilly in Q4 2013 and has held it in 42 quarters since.
- 4,598 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.